SBWire

Global Market Direct's pharmaceuticals report, "Sanofi Pasteur SA - Product Pipeline Review - 2013" provides data on the Sanofi Pasteur SA's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "Neurotec Pharma SL - Product Pipeline Review - 2013" provides data on the Neurotec Pharma SL's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Markets Direct's, 'Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Recurrent Glioblastoma Multiforme (GBM), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Recurrent Glioblastoma Multiforme (GBM). Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Global Markets Direct's, 'Retinoblastoma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Retinoblastoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Retinoblastoma. Retinoblastoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Global Markets Direct's, 'Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Alpha- Antitrypsin Deficiency, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Alpha- Antitrypsin Deficiency. Alpha- Antitrypsin Deficiency - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Global Market Direct's pharmaceuticals report, "Synthetic Biologics, Inc. - Product Pipeline Review - 2013" provides data on the Synthetic Biologics, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "Immunovative Therapies, Ltd. - Product Pipeline Review - 2013" provides data on the Immunovative Therapies, Ltd.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

One among them is the very renowned Durex’s Intimate Sensilube Fluid Lubricant which can be applied on intimate parts for a sensuous penetration during the act. The lubricant can also be used as a condom sensation; http://www.pharmexpert.fr/durex.html

Global Market Direct's pharmaceuticals report, "CalAsia Pharmaceuticals, Inc. - Product Pipeline Review - 2013" provides data on the CalAsia Pharmaceuticals, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "Hanmi Pharmaceuticals, Co. Ltd. - Product Pipeline Review - 2013" provides data on the Hanmi Pharmaceuticals, Co. Ltd.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "Innopharmax Inc. - Product Pipeline Review - 2013" provides data on the Innopharmax Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "Novabiotics Ltd - Product Pipeline Review - 2013" provides data on the Novabiotics Ltd's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "AnGes MG, Inc. - Product Pipeline Review - 2013" provides data on the AnGes MG, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Markets Direct's, 'Bacteremia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bacteremia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bacteremia. Bacteremia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Global Market Direct's pharmaceuticals report, "Philogen S.p.A. - Product Pipeline Review - 2013" provides data on the Philogen S.p.A.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Markets Direct's, 'Swine Influenza - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Swine Influenza, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Swine Influenza. Swine Influenza - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Global Market Direct's pharmaceuticals report, "Lipella Pharmaceuticals, Inc. - Product Pipeline Review - 2013" provides data on the Lipella Pharmaceuticals, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "Pharnext SAS - Product Pipeline Review - 2013" provides data on the Pharnext SAS's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Markets Direct's, 'Intermittent Claudication - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Intermittent Claudication, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Intermittent Claudication. Intermittent Claudication - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Global Markets Direct's, 'Pompe Disease - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Pompe Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pompe Disease. Pompe Disease - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Global Market Direct's pharmaceuticals report, "Inotek Pharmaceuticals Corporation - Product Pipeline Review - 2013" provides data on the Inotek Pharmaceuticals Corporation's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "Abbvie Inc. - Product Pipeline Review - 2013" provides data on the Abbvie Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Markets Direct's, 'Mixed Dyslipidemia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Mixed Dyslipidemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mixed Dyslipidemia. Mixed Dyslipidemia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Global Market Direct's pharmaceuticals report, "ArmaGen Technologies, Inc. - Product Pipeline Review - 2013" provides data on the ArmaGen Technologies, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Markets Direct's, 'Hemorrhage - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hemorrhage, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hemorrhage. Hemorrhage - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.